In a recent study, recombinant IL-7 increased CD8+ and CD4+ T cell proliferation (ex vivo) in critically ill COVID-19 patients (27), and IL-7 has been suggested as immunotherapy and/or a vaccine adjuvant for COVID-19 (27–29). This evidence concerns the gene CD8A and COVID-19.